Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GJB2 | P29033 | 1/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.46 |
| ▸ | SELP | P16109 | 3/20 | 0.46 |
| ▸ | SELE | P16581 | 3/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092453 | 1.00 | MAPK1 (0.55) | MAPK1GJB2SELLSELPSELE | |
| SCHEMBL14506448 | 1.00 | MAPK1 (0.55) | MAPK1GJB2SELLSELPSELE | |
| SCHEMBL30391777 | 0.99 | MAPK1 (0.53) | MAPK1GJB2SELLSELPSELE | |
| SCHEMBL25672964 | 0.94 | GJB2 (0.49) | MAPK1GJB2MMP13 | |
| SCHEMBL18392190 | 0.93 | MAPK1 (0.58) | MAPK1GJB2 | |
| SCHEMBL15247047 | 0.93 | GJB2 (0.58) | MAPK1GJB2MMP13 | |
| SCHEMBL18357218 | 0.93 | GJB2 (0.58) | MAPK1GJB2MMP13 | |
| SCHEMBL12972816 | 0.93 | GJB2 (0.58) | MAPK1GJB2MMP13 | |
| SCHEMBL16640877 | 0.92 | GJB2 (0.46) | MAPK1GJB2MMP13 | |
| SCHEMBL16509365 | 0.91 | GJB2 (0.58) | MAPK1GJB2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408045-B1 | NOVEL GALACTOSYLCERAMIDE ANALOGS AND BETA-GLUCOCEREBROSIDASE ACTIVATORS,EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING BETA-GLUCOCEREBROSIDASE USING THE ANALOGS | KAO CORP (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20070111951-A1 | Novel galactosylceramide analogues, and beta-glucocerebrosidase activator, external skin preparations and method of activating beta-glucocerebrosidase using the same | KAO CORPORATION | 2007-05-17 | — | — | US | disclosed |
| US-7183261-B2 | Galactosylceramide analogs, and β-glucocerebrosidase activators, external skin preparations and method of activating β-glucocerebrosidase using the analogs | KAO CORPORATION (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040242499-A1 | Novel galactosylceramide analogs, and beta-glucocerebrosidase activators, external skin preparations and method of activating beta-glucocerebrosidase using the analogs | KAO CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1408045-A1 | NOVEL GALACTOSYLCERAMIDE ANALOGS AND BETA-GLUCOCEREBROSIDASE ACTIVATORS,EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING BETA-GLUCOCEREBROSIDASE USING THE ANALOGS | Kanebo, Limited (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111951-A1 | Novel galactosylceramide analogues, and beta-glucocerebrosidase activator, external skin preparations and method of activating beta-glucocerebrosidase using the same | GBA1, GALC, GBA2 | MAPK1 2538/4885GJB2 1115/4885SELL 3742/4885 |
| US-20040242499-A1 | Novel galactosylceramide analogs, and beta-glucocerebrosidase activators, external skin preparations and method of activating beta-glucocerebrosidase using the analogs | GBA1, GALC, GBA2 | MAPK1 1866/4885GJB2 846/4885SELL 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.